MedTrace Logo

IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin

NCT00654446 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 442

Last updated 2009-03-16

No results posted yet for this study

Summary

The purpose of this study is to assess the effects on the kidney of rosuvastatin and simvastatin in subjects with Fredrickson Type IIa \& Type IIb Dyslipidaemia

Conditions

  • Fredrickson Type IIa & Type IIb Dyslipidaemia

Interventions

DRUG

Rosuvastatin

DRUG

Simvastatin

Sponsors & Collaborators

Principal Investigators

  • Evan Stein · Metabolic & Athersclerotic research centre, Cincinatti, USA

  • Russell Esterline · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Completion
2004-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00654446 on ClinicalTrials.gov